Embed Size (px)
Citation preview
COLLABORATION
PARTNERSHIPS
QUOTES FROM A RECENT
TRANSACTION PARTNER
SCIENCE
SP
EE
D
AC
CE
SS
IBLE
CUTTING EDGE
PR
OV
EN
TR
AC
K R
EC
OR
D
“We had a number of attractive strategic options in front of us, however Bristol-Myers Squibb and its focus on exploring our biology won the day.”
“Bristol-Myers Squibb was the right partner who brought the optimal deal structure, considerable capabilities and a commitment of resources.”
Anna Rivkin Global Lead, Fibrotic Diseases [email protected]
Mohamed Ragab Head, Immuno-Oncology/Oncology [email protected]
Timothy Fisher Global Lead, Immuno-Oncology/Oncology [email protected]
Saryah Azmat Manager, Immuno-Oncology/Oncology [email protected]
Fang Zhang Manager, Immuno-Oncology/Oncology [email protected]
TECHNOLOGY TRANSACTIONS
Donnie McGrath Vice President, Search and Evaluation
Steve Yoder Head, Specialty [email protected]
Martin Crook Global Lead, Cardiovascular [email protected]
Mireia Gomez-Angelats Global Lead, Genetically Defined Diseases [email protected]
Stephen O’Keefe Global Lead, Immunoscience stephen.o’[email protected]
SEARCH AND EVALUATION
Graham Brazier Vice President, Transactions
Matt Bunn Genomics, Bioinformatics and Clinical Imaging [email protected]
Michael Cucolo Drug Delivery and Formulation Sciences [email protected]
Andrea Lauber Clinical Biomarkers and Pharmacodiagnostics [email protected]
Karen Martell Biologics Discovery Platforms [email protected]
Rob Penhallow Chemistry and ADME/Toxicology [email protected]
Ping Cao Lead Discovery and Optimization and Protein Sciences and Structure [email protected]
BUSINESS DEVELOPMENT CONTACTS
- Paul Biondi, Senior Vice President & Head of Business Development ”“We have a distinct, decisive approach to partnering that leverages our best with the best of our partners to speed transformational medicines to patients.
Combining passion, science and experience to deliver innovation together
PARTNERING TO SPEED TRANSFORMATIONAL
MEDICINES TO PATIENTS
5asdFor more information please visit: www.bms.com/partnering
5asd
TECHNOLOGY INTERESTS
“”
External innovation and collaboration has been a critical component to building our differentiated portfolio of specialty medicines and a hallmark of our success.- Giovanni Caforio, M.D. Chief Executive Officer
DRUG PLATFORMS AND NOVEL TECHNOLOGIES
• Access to new chemical matter, including macrocycle and fragment libraries
• Novel antibody drug conjugate (ADC) technology
• Subcutaneous controlled release
• Oral delivery of millamolecules and macrocyclic peptides
• ADME/Toxicology: Modeling and prediction technology
• High throughput, label free screening and protein expression platform
• Emerging structure determination platform
• Non-invasive diagnostics and translational biomarkers
• Improved methods for single cell capture, and genomic characterization
• Scalable bioinformatics analysis capabilities using principles for reproducible research
OUR STRATEGIC FOCUS - 2016
Immuno-Oncology
• Focus on approaches that are direct acting on the immune system
- Novel immune checkpoint inhibitors and co-stimulatory agents
• Tumor intrinsic targets with demonstrated impact on anti-tumor immunity
• Tumor microenvironment
Oncology • Agents displaying synergy with immune
checkpoint inhibitors
• Established non-immunosuppressive mechanisms of action
• New approaches to validated cancer pathways
• Emerging areas of cancer biology
• Antibody drug conjugates (ADC) – novel targets and late preclinical/clinical-stage programs in areas of unmet medical need
Out of Scope: Supportive care – Bristol-Myers Squibb focuses on therapeutics
Immunoscience • Assets with transformative potential in inflamma-
tory arthritis, SLE/lupus nephritis, IBD and other immune-mediated diseases with high unmet needs
Out of Scope: allergy and asthma
Cardiovascular • Heart failure: acute, post-acute, HFrEF,
HFpEF, cardiomyopathy
• Highly validated targets addressing CV risk with clear specialty medicine development paths
Out of Scope: LDL lowering, HDL raising, anticoagulant, hypertension
Fibrosis • Mechanisms which selectively block fibroblast
and stellate cell activation, or enhance productive healing through pro-resolution macrophages
• Modulation of TGF-β pathway in a tissue or cell specific manner. Selectively modulate myofibroblast activity via the TGF-β pathway
• Target regenerative mechanisms with potential for fibrosis reversal and repair
• Mechanisms which promote extracellular matrix turnover or epithelial cell protection
• Non-invasive diagnostics and biomarkers which correlate with disease pathology, or facilitate identification of patients who are likely to progresses rapidly, or enable identification of patients likely to respond to therapies
• Priority fibrotic diseases include: NASH fibrosis; NASH cirrhosis, Idiopathic Pulmonary Fibrosis (IPF); Fibrotic Interstitial Lung diseases
Genetically Defined Diseases (GDD)
• Focus on monogenic diseases
• Clinical-stage opportunities in rare/orphan diseases targeting at or near mutant protein
• Special interest in clinical and preclinical opportunities targeting Duchenne Muscular Dystrophy, synuclein, Nav1.7, and familial cardiomyopathy (fCM – hypertrophic or dilated)
BRISTOL-MYERS SQUIBB DEVELOPMENT PORTFOLIO BY DISEASE AREA
Data as of May 1, 2016
1 Approved in at least one major market (US, EU, JP)
2 In Phase III development or currently under regulatory review
Marketed 1
Phase III 2
Phase II
Phase I
▶ ACTIVE PARTNERSHIP
SOURCED INNOVATION
Genetically Defined Diseases
Anti-Myostatin
Anti-eTau
Oncology
SPRYCEL
BET Inhibitor
Ulocuplumab (Anti-CXCR4)
Anti-Fucosyl GM1
Anti-HER2
Mesothelin ADC
Fibrotic Diseases
PEG-FGF21 (1)
Galectin-3 Inhibitor
LPA1 Antagonist
Pentraxin-2
PEG-FGF21(2)
Immuno-Oncology
YERVOY
OPDIVO
EMPLICITI
PROSTVAC
Urelumab (Anti-CD137)
Lirilumab (Anti-KIR)
Anti-LAG3
▶▶
Anti-GITR
Anti-CSF 1R
▶▶
▶▶
IDO Inhibitor
Immunoscience
ORENCIA
NULOJIX
Lulizumab (Anti-CD28)
BTK Inhibitor
Anti-CD40L
Anti-CD40
TYK2 Inhibitor
▶
Anti-PD-L1
Cardiovascular
ELIQUIS
IKur Inhibitor
Factor XIa Inhibitor
PAR4 Antagonist
Nitroxyl Donor
▶
Global product names appearing in italics represent the BMS-owned registered U.S. trademark for that product; however, PROSTVAC is a trademark of BN ImmunoTherapeutics Inc.
Gene TherapyRNA Oligonucleotides
Small Molecules Biologics
Antibody Drug Conjugates Millamolecules
Drug Delivery Technology
